Novo Nordisk Juggles Gulf Expansion, Medicare Entry and Make-or-Break Clinical Results in Bid to Rekindle Investor Confidence
Published on 06/04/2026 at 13:31 | Redaktion boerse-global.de
The month of June is shaping up as a crucible for Novo Nordisk, with the Danish drugmaker facing a rare convergence of regulatory, clinical and commercial milestones. From next week’s pivotal data readouts at the American Diabetes Association meeting to the first-ever Medicare coverage of obesity drugs starting July 1, the company has a packed agenda that could either restore faith in its pipeline or amplify the pricing anxieties that have hammered its stock.
That share price has been under relentless pressure. After closing Wednesday at €36.40, the stock eked out a 1.03% gain on Thursday to €36.77, but the longer-term picture remains bleak: a decline of 18.54% since the start of the year and a 42.05% slide over the past twelve months. The shares now trade 11.85% below their 200-day moving average, with a relative strength index of 44.9 signalling neutral momentum.
Medicare Breaks a Long-Standing Taboo
Perhaps the most transformative near-term catalyst is the Medicare expansion. Starting 1 July, eligible beneficiaries with obesity will gain access to both the injectable and tablet versions of Wegovy for a monthly copay of $50. The move breaks a federal prohibition that had kept Medicare from covering prescription drugs solely for weight management, and it opens the door to millions of new patients.
Novo Nordisk and rival Eli Lilly have agreed to a net monthly price of $245 — a sharp discount from list prices that routinely exceed $1,000. The programme runs through to the end of 2027, offering a clear volume opportunity. Yet the trade-off is equally clear: lower realised prices will squeeze margins, especially in the US market that already accounts for the bulk of Novo Nordisk’s GLP-1 revenue. The company has warned that 2026 group revenue and operating profit could fall by 5% to 13%, citing lower US net prices, reduced Medicaid reimbursements for obesity therapies and the impact of most-favoured-nation pricing arrangements.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Oral Wegovy Crosses Borders
While the Medicare deal addresses the US reimbursement puzzle, Novo Nordisk is simultaneously testing its international distribution capabilities. The company has launched the oral tablet version of Wegovy in the United Arab Emirates — the first market outside the US where patients can access the pill. The Emirates Drug Establishment approved oral semaglutide for long-term weight management and cardiovascular risk reduction, a decision with practical significance given that roughly 28% of adults in the UAE are classified as obese.
The tablet has a logistical edge over the injectable: it requires no cold chain, making it far easier to slot into standard pharmaceutical supply chains. Novo Nordisk’s Emil Kongshøj Larsen expects local pharmacies to stock the product within days. Monthly treatment costs range from about 740 to 1,700 dirham, close to the price of the injectable formulation.
The US launch has already set a high bar. In the first quarter of 2026, the Wegovy pill generated 2.26 billion Danish kroner in revenue, nearly doubling the consensus estimate of 1.16 billion. Around 1.3 million prescriptions were filled in the first three months, and by May the drug had captured 65% of all new prescriptions in the US weight-loss market. Further international rollouts of the oral version are scheduled for selected markets in the second half of the year.
Not all governments, however, are eager to cover the cost. Belgium’s health minister, Frank Vandenbroucke, announced on Thursday that the country will not reimburse Wegovy under the state scheme. The reimbursement committee had warned that broad coverage could consume more than 50% of the national drugs budget — a stark reminder of the affordability challenge that obesity drugs pose to European healthcare systems.
Pipeline Data Takes Centre Stage
Against this commercial backdrop, the scientific calendar is unusually heavy. From 5 to 8 June, Novo Nordisk will present 40 abstracts at the ADA’s Scientific Sessions in New Orleans. The headline act is the phase 3 REIMAGINE programme for CagriSema, a weekly injection combining cagrilintide and semaglutide that targets both blood glucose control and weight loss in patients with type 2 diabetes. The company also plans to release phase 2b data on Zenagamtid, a dual GLP-1 and amylin receptor agonist that could differentiate itself from existing therapies. Updated real-world evidence on Ozempic and Wegovy in cardiometabolic diseases will round out the presentation.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
A dedicated R&D investor meeting is scheduled for 7 June at 6:30 p.m. local time. CagriSema has been under review by the US Food and Drug Administration since December 2025, with a decision expected in the fourth quarter of 2026 and a potential market launch in early 2027. Good data from REIMAGINE would bolster the argument that Novo Nordisk can sustain its GLP-1 leadership beyond the current generation of semaglutide — especially as exclusivity on that molecule starts to expire in some international markets.
The company has also been deploying its balance sheet: a share buyback programme of up to 15 billion Danish kroner, launched on 4 February, had already returned 4.71 billion kroner through 29 May, covering 17.89 million B-shares.
What emerges from this month’s events will shape not just the immediate share price trajectory but also the longer-term narrative. A convincing clinical showing at ADA would give investors a tangible counterweight to pricing pressure. But if the data are merely solid, the Medicare volume boost — welcome though it is — may not be enough to offset the structural margin compression that is now baked into Wall Street’s forecasts.
Ad
Novo Nordisk Stock: New Analysis - 4 June
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
